David Rimm

David Rimm is the Anthony N. Brady Professor of Pathology in the Departments of Pathology and Medicine (Oncology) at Yale University School of Medicine. He serves as Director of Yale Pathology Tissue Services and the Lab for Quantitative Diagnostics in Anatomic Pathology. Dr. Rimm is a leading researcher in quantitative pathology with over 500 peer-reviewed publications and an H-index of 120.

Dr. Rimm completed his MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His academic journey has positioned him as a key figure in cancer biomarker research and diagnostic development.

Dr. Rimm's research primarily focuses on quantitative pathology and cancer biomarker development. His lab pioneered the AQUA method of quantitative immunofluorescence, published in Nature Medicine in 2002, which has been cited over 875 times. His current work involves developing quantitative methods for predicting response and resistance to targeted and immune-therapy in cancer, with particular focus on breast, lung, and melanoma cancers. His lab utilizes high-plex methods including digital spatial profiling for new biomarker discovery and is actively working on standardization of assays for CLIA labs.

Analysis of Dr. Rimm's recent publications (2024-2025) reveals a strong focus on quantitative biomarker development for precision oncology, particularly in breast cancer, lung cancer, and melanoma. His work spans from basic method development (quantitative immunofluorescence, AI-driven assessment) to clinical application (companion diagnostics, HER2 testing, antibody-drug conjugate therapies). The publications demonstrate a consistent theme of translating quantitative pathology methods into clinical practice.

• Lauren Ackerman Lectureship (2008)
• Starwood Commitment Award (2004)

Dr. Rimm's research is supported by grants from the NIH, Breast Cancer Research Foundation (BCRF), and sponsored research agreements from biopharma companies. His lab actively collaborates with industry partners to translate research findings into clinical applications. With over 500 publications and 8 patents, his work has significant impact in the field of quantitative pathology and cancer diagnostics.

Dr. Rimm leads the Rimm Lab for Quantitative Diagnostics in Anatomic Pathology, which focuses on developing innovative quantitative approaches to pathology. The lab's work spans from basic research on quantitative methods to clinical translation of diagnostic assays. The lab utilizes tissue microarray technology, high-plex in situ assessment, and quantitative imaging to predict response to cancer therapies.